




RealRate

PHARMACEUTICAL 2015

Anacor Pharmaceuticals Inc
Rank 77 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Anacor Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anacor Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 104% points. The greatest weakness of Anacor Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 340%, being 87% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	160,570
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	28,653
Liabilities, Non-Current	0
Other Assets	46,835
Other Compr. Net Income	-143
Other Expenses	1,856
Other Liabilities	0
Other Net Income	-2,091
Other Revenues	20,686
Property and Equipment	1,642
Research and Development	72,493
Selling, General and Administrative Expense	31,392

Output Variable	Value in 1000 USD
Assets	209,047
Liabilities	28,653
Expenses	105,741
Revenues	20,686
Stockholders Equity	180,394
Net Income	-87,146
Comprehensive Net Income	-87,218
BaseVar	183,180
ECR before LimitedLiability	258%
Economic Capital Ratio	340%